tiprankstipranks
Trending News
More News >
CellSeed Inc. (JP:7776)
:7776
Japanese Market
Advertisement

CellSeed Inc. (7776) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7776

CellSeed Inc.

(7776)

Rating:52Neutral
Price Target:
¥510.00
▲(5.81% Upside)
CellSeed Inc.'s overall stock score is primarily influenced by its financial performance, which highlights significant challenges in profitability and cash flow. Technical analysis suggests a neutral to slightly bearish trend, while valuation metrics are poor due to negative earnings. The absence of earnings call insights and corporate events means these factors do not impact the score.

CellSeed Inc. (7776) vs. iShares MSCI Japan ETF (EWJ)

CellSeed Inc. Business Overview & Revenue Model

Company DescriptionCellSeed Inc. (7776) is a biotechnology company specializing in regenerative medicine. The company focuses on the development and commercialization of cell sheet engineering technology, which is used in regenerative treatments for damaged tissues and organs. Their core products and services include cell sheet regenerative therapies and related research and development activities aimed at advancing tissue regeneration technology.
How the Company Makes MoneyCellSeed Inc. generates revenue primarily through the development and licensing of its proprietary cell sheet engineering technology. The company partners with medical institutions and pharmaceutical companies to develop regenerative therapies, earning income from licensing fees, research and development collaborations, and milestone payments. Additionally, CellSeed Inc. may generate revenue from the sale of its regenerative medicine products once they receive regulatory approval and are commercialized.

CellSeed Inc. Financial Statement Overview

Summary
CellSeed Inc. faces significant financial challenges, particularly in profitability and operational cash flows. The balance sheet remains stable with strong equity, but ongoing net losses and negative cash flows highlight the need for strategic changes to improve financial health and sustainability.
Income Statement
45
Neutral
CellSeed Inc. shows a consistent negative EBIT and net income over the years, indicating ongoing operational challenges. Gross profit margin has declined significantly from 2019 to 2024, reflecting increased cost pressures. Revenue growth has been volatile, with declines in recent years, suggesting struggles in maintaining sales momentum.
Balance Sheet
60
Neutral
The company's balance sheet shows a strong equity position with a high equity ratio, indicating financial stability. However, the consistent net losses have impacted return on equity negatively. Debt levels remain low, reducing leverage risk, but stagnant equity growth poses challenges for future financing.
Cash Flow
50
Neutral
CellSeed Inc.'s cash flow statement highlights negative operating and free cash flows, which are concerning for liquidity and operational sustainability. Despite significant financing activities, the reliance on external funding may not be sustainable long-term. The cash flow to net income ratio indicates challenges in converting earnings to cash.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue193.28M190.13M126.43M161.67M199.47M
Gross Profit110.11M107.16M61.02M84.04M138.19M
EBITDA-855.49M-836.52M-750.00M-905.67M-770.13M
Net Income-859.84M-846.53M-759.68M-912.87M-783.86M
Balance Sheet
Total Assets2.43B2.47B1.54B1.41B1.81B
Cash, Cash Equivalents and Short-Term Investments2.13B2.16B1.07B846.67M1.46B
Total Debt143.75M151.25M158.75M160.00M160.00M
Total Liabilities269.88M301.05M365.58M363.58M280.08M
Stockholders Equity2.16B2.16B1.18B1.04B1.53B
Cash Flow
Free Cash Flow-884.47M-801.07M-733.60M-908.15M-710.96M
Operating Cash Flow-866.10M-779.43M-718.01M-817.15M-700.68M
Investing Cash Flow-18.37M56.31M61.73M-110.44M-12.62M
Financing Cash Flow855.48M1.81B881.81M396.88M1.10B

CellSeed Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price482.00
Price Trends
50DMA
474.16
Positive
100DMA
504.46
Negative
200DMA
470.72
Positive
Market Momentum
MACD
2.52
Negative
RSI
52.88
Neutral
STOCH
79.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7776, the sentiment is Positive. The current price of 482 is above the 20-day moving average (MA) of 472.40, above the 50-day MA of 474.16, and above the 200-day MA of 470.72, indicating a bullish trend. The MACD of 2.52 indicates Negative momentum. The RSI at 52.88 is Neutral, neither overbought nor oversold. The STOCH value of 79.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7776.

CellSeed Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
¥9.67B38.52
4.58%-39.30%
58
Neutral
¥20.39B
6.33%-250.29%
52
Neutral
¥17.47B
-22.81%2.69%
51
Neutral
$7.95B-0.38-43.43%2.22%22.30%-1.83%
51
Neutral
¥25.41B393.39
-27.00%
49
Neutral
¥18.57B206.40
13.83%34.66%
47
Neutral
¥19.45B
8.47%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7776
CellSeed Inc.
482.00
-405.00
-45.66%
JP:4599
StemRIM Inc.
313.00
-100.00
-24.21%
JP:4889
Renascience Inc.
1,965.00
1,600.00
438.36%
JP:4978
ReproCELL Inc.
195.00
66.00
51.16%
JP:7096
StemCell Institute
956.00
-635.57
-39.93%
JP:7774
Japan Tissue Engineering Co., Ltd.
499.00
-28.00
-5.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 04, 2025